Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.

about

Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.

Item

http://www.wikidata.org/entity/Q38894023

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Effect of Anti-TNF Agents on P ...... Single Institution Experience.

@en

type

Item

label

Effect of Anti-TNF Agents on P ...... Single Institution Experience.

@en

prefLabel

Effect of Anti-TNF Agents on P ...... Single Institution Experience.

@en

P1476

Effect of Anti-TNF Agents on P ...... Single Institution Experience.

@en

P2093

Adam C Fields

http://www.w3.org/2001/XMLSchema#string

Brian D Cohen

http://www.w3.org/2001/XMLSchema#string

Celia M Divino

http://www.w3.org/2001/XMLSchema#string

Chaya Shwaartz

http://www.w3.org/2001/XMLSchema#string

Maximiliano Sobrero

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis

Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Certolizumab pegol for the treatment of Crohn's disease

Infliximab for induction and maintenance therapy for ulcerative colitis

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease.

Hand suture versus stapler for closure of loop ileostomy--a systematic review and meta-analysis of randomized controlled trials.

Clinical pharmacokinetics of TNF antagonists: how do they differ?

P2888

s11605-016-3194-z

P304

1636-1642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11605-016-3194-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27405310

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

TNF

inflammatory bowel diseases